Effects of Mesoglycan Sulfate on the Arterial Elastic Module

Andreozzi, Giuseppe Maria; Signorelli, Salvatore Santo; Duca, S; Minacapelli, Concetta; Amico‐Roxas, M.; Minardo, G.; Cacciaguerra, Giuseppe

doi:10.1177/000331978703800803

Cited by 7 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, the inci dence of adverse effects observed with ASA was similar to that reported by other investigators [2][3][4][5], while a signifi cantly lower number of adverse experiences were reported during mesoglycan treatment. This confirms previous ob servations on the good tolerability of the drug [26][27][28][29].…”

Section: Discussionsupporting

confidence: 90%

“…Studies in patients with cerebral or peripheral vascular diseases with thrombotic risk have shown improvement of symptoms after parenteral or oral administration of mesoglycan [26][27][28], while preliminary data have suggested that, similarly to antiplatelet agents, the drug may be effective in secondary prevention of cere brovascular events [29].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A Randomized, ASA-Controlled Trial of Mesoglycan in Secondary Prevention after Cerebral Ischemic Events

Forconi¹,

Battistini²,

Guerrini³

et al. 1995

Cerebrovasc Dis

View full text Add to dashboard Cite

The aim of this randomized, open, parallel-group study was to compare the efficacy and tolerability of mesoglycan, a glycosaminoglycan preparation, and acetylsalicylic acid (ASA) in prevention of vascular events after cerebral ischemic events. In 48 collaborating centers we followed a total of 1,398 patients with recent episodes of reversible ischemic attacks or stroke of atherothrombotic origin, randomized to mesoglycan (701 patients) or ASA (697 patients). During the observation period patients'' new events were recorded: primary outcome events were considered reversible ischemic neurologic deficits, stroke, acute myocardial infarction or death from other vascular causes. At the end of the follow-up period (median duration 18 months) the number of primary outcome events observed in the two treatment groups was similar (68 in the ASA, 70 in the mesoglycan group). Major stroke was observed in 24 patients of the ASA group and in 26 of the mesoglycan group, while deaths from vascular causes were 37 and 32, respectively. Log-rank statistics failed to evidence significant differences between treatment groups. On the other hand, a significantly (p < 0.01, chi square test) higher incidence of side effects was reported in the ASA group (146 vs. 50). The findings of the present investigation are promising and suggest that further studies on mesoglycan as an antithrombotic agent in the secondary prevention of vascular events are warranted.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

A Randomized, ASA-Controlled Trial of Mesoglycan in Secondary Prevention after Cerebral Ischemic Events

Forconi¹,

Battistini²,

Guerrini³

et al. 1995

Cerebrovasc Dis

View full text Add to dashboard Cite

show abstract

“…Andreozzi et al [18] evaluated the use of mesoglycan in patients with peripheral obstructive arterial disease (POAD). Ten patients with PAOD in stages I and II according to Leriche-Fontaine were treated with mesoglycan sulfate (60 mg daily for twenty days) to evaluate the effects of the drug on the elastic modulus of the arterial wall.…”

Section: Clinical Studiesmentioning

confidence: 99%

“…Ten patients with PAOD in stages I and II according to Leriche-Fontaine were treated with mesoglycan sulfate (60 mg daily for twenty days) to evaluate the effects of the drug on the elastic modulus of the arterial wall. The wall elasticity was deduced from some Doppler velocitographic indices: arterial dynamics index (ADI), resistance index (RI), perfusion pressure index (PPI), and tibial distensibility index (TDI) from the analysis of systolic, protodiastolic, and end-diastolic velocity variations and from computerized analysis of the Doppler sound spectrum [18]. The treatment with mesoglycan sulfate induced: (1) a reduction of mean RI and PPI, which expresses a reduction of the peripheral resistance on the arteriolo-capillary side and, thus, a better endothelial function; (2) a reduction in the worsening of the mean percent variations of the systolic window induced by ischemia, which is a sign of a more homogeneous flow of the blood particles inside the vessel and of a better wall responsiveness; and (3) an improvement of the wall response to the vasodilator stimulus [18].…”

Section: Clinical Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Mesoglycan: Clinical Evidences for Use in Vascular Diseases

Tufano¹,

Arturo²,

Cimino³

et al. 2010

International Journal of Vascular Medicine

View full text Add to dashboard Cite

Vascular glycosaminoglycans (GAG) are essential components of the endothelium and vessel wall and have been shown to be involved in several biologic functions. Mesoglycan, a natural GAG preparation, is a polysaccharide complex rich in sulphur radicals with strong negative electric charge. It is extracted from porcine intestinal mucosa and is composed of heparan sulfate, dermatan sulfate, electrophoretically slow-moving heparin, and variable and minimal quantities of chondroitin sulfate. Data on antithrombotic and profibrinolytic activities of the drug show that mesoglycan, although not indicated in the treatment of acute arterial or venous thrombosis because of the low antithrombotic effect, may be useful in the management of vascular diseases, when combined with antithrombotics in the case of disease of cerebral vasculature, and with antithrombotics and vasodilator drugs in the case of chronic peripheral arterial disease. The protective effect of mesoglycan in patients with venous thrombosis and the absence of side effects, support the use of GAG in patients with chronic venous insufficiency and persistent venous ulcers, in association with compression therapy (zinc bandages, multiple layer bandages, etc.), elastic compression stockings, and local care, and in the prevention of recurrences in patients with previous DVT following the standard course of oral anticoagulation treatment.

show abstract

RETRACTED: Mesoglycan exerts its fibrinolytic effect through the activation of annexin A2

Belvedere

Morretta

Pessolano

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Mesoglycan is a drug based on a mixture of glycosaminoglycans mainly used for the treatment of blood vessel diseases acting as antithrombotic and profibrinolytic drugs. Besides the numerous clinical studies, there is no information about its function on the fibrinolytic cascade. Here, we have elucidated the mechanism of action by which mesoglycan induces the activation of plasmin from endothelial cells. Surprisingly, by a proteomic analysis, we found that, following mesoglycan treatment, these cells show a notable amount of annexin A2 (ANXA2) at the plasma membrane. This protein has been widely associated with fibrinolysis and appears able to move to the membrane when phosphorylated. In our model, this translocation has proven to enhance cell migration, invasion, and angiogenesis. Furthermore, the interaction of mesoglycan with syndecan 4 (SDC4), a coreceptor belonging to the class of heparan sulfate proteoglycans, represents the upstream event of the ANXA2 behavior. Indeed, the activation of SDC4 triggers the motility of endothelial cells culminating in angiogenesis. Interestingly, mesoglycan can induce the release of plasmin in endothelial cell supernatants only in the presence of ANXA2. This evaluation suggests that mesoglycan triggers the formation of a chain mechanism starting from the activation of SDC4, and the related cascade of events, including src complex and PKCα activation, promoting the phosphorylation of ANXA2 and its translocation to plasma membrane. This indicates a connection among mesoglycan, SDC4‐(PKCα‐src), and ANXA2 which, in turn, links the tissue plasminogen activator bringing it closer to plasminogen. This latter is so cleaved to release the plasmin and degrade fibrin sleeves.

show abstract

Effects of Mesoglycan Sulfate on the Arterial Elastic Module

Cited by 7 publications

References 12 publications

A Randomized, ASA-Controlled Trial of Mesoglycan in Secondary Prevention after Cerebral Ischemic Events

A Randomized, ASA-Controlled Trial of Mesoglycan in Secondary Prevention after Cerebral Ischemic Events

Mesoglycan: Clinical Evidences for Use in Vascular Diseases

RETRACTED: Mesoglycan exerts its fibrinolytic effect through the activation of annexin A2

Contact Info

Product

Resources

About